{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:21:27Z","timestamp":1782958887922,"version":"3.54.5"},"reference-count":317,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.pnpbp.2024.111069","type":"journal-article","created":{"date-parts":[[2024,6,24]],"date-time":"2024-06-24T05:14:58Z","timestamp":1719206098000},"page":"111069","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Alzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates"],"prefix":"10.1016","volume":"134","author":[{"given":"Jana","family":"Hroudov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zden\u011bk","family":"Fi\u0161ar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.pnpbp.2024.111069_bb0005","first-page":"149","article-title":"Clinical effects of Tramiprosate in APOE4\/4 homozygous patients with mild Alzheimer\u2019s disease suggest disease modification potential","volume":"4","author":"Abushakra","year":"2017","journal-title":"J. Prev Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bib1568","first-page":"LB23","article-title":"Abstract: Symposia, Conferences, Oral communications: 13th Clinical Trials on Alzheimer\u2019s Disease (CTAD) November 4-7, 2020","volume":"7","author":"Aceves","year":"2020","journal-title":"J. Prev. Alzheimers Dis."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0010","doi-asserted-by":"crossref","first-page":"662","DOI":"10.3389\/fneur.2018.00662","article-title":"Does severity of Alzheimer\u2019s disease contribute to its responsiveness to modifying gut microbiota? A double blind clinical trial","volume":"9","author":"Agahi","year":"2018","journal-title":"Front. Neurol."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0015","doi-asserted-by":"crossref","first-page":"E156","DOI":"10.1152\/ajpendo.00642.2020","article-title":"Insulin action in the brain regulates both central and peripheral functions","volume":"321","author":"Agrawal","year":"2021","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0020","doi-asserted-by":"crossref","first-page":"256","DOI":"10.3389\/fnagi.2016.00256","article-title":"Effect of probiotic supplementation on cognitive function and metabolic status in Alzheimer\u2019s disease: a randomized, double-blind and controlled trial","volume":"8","author":"Akbari","year":"2016","journal-title":"Front. Aging Neurosci."},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111069_bb0025","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1365-2710.2009.01133.x","article-title":"Saffron in the treatment of patients with mild to moderate Alzheimer\u2019s disease: a 16-week, randomized and placebo-controlled trial","volume":"35","author":"Akhondzadeh","year":"2010","journal-title":"J. Clin. Pharm. Ther."},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb0030","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1007\/s00213-009-1706-1","article-title":"A 22-week, multicenter, randomized, double-blind controlled trial of Crocus sativus in the treatment of mild-to-moderate Alzheimer\u2019s disease","volume":"207","author":"Akhondzadeh","year":"2010","journal-title":"Psychopharmacology"},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111069_bb0035","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.jalz.2011.03.008","article-title":"The diagnosis of mild cognitive impairment due to Alzheimer\u2019s disease: recommendations from the National Institute on Aging-Alzheimer\u2019s Association workgroups on diagnostic guidelines for Alzheimer\u2019s disease","volume":"7","author":"Albert","year":"2011","journal-title":"Alzheimers Dement."},{"issue":"6","key":"10.1016\/j.pnpbp.2024.111069_bb0040","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/brain\/awz100","article-title":"Prevention of tau seeding and propagation by immunotherapy with a central tau epitope antibody","volume":"142","author":"Albert","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.pnpbp.2024.111069_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/07317115.2023.2209563","article-title":"The effect of Cannabidiol 3% on neuropsychiatric symptoms in dementia - six-month follow-up","author":"Alexandri","year":"2023","journal-title":"Clin. Gerontol."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0050","first-page":"1","article-title":"Advanced Alzheimer\u2019s disease patients show safe, significant, and persistent benefit in 6-month Bryostatin trial","volume":"Preprint","author":"Alkon","year":"2023","journal-title":"J. Alzheimers Dis."},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111069_bb0055","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s10787-023-01163-7","article-title":"Long-term use of metformin and Alzheimer\u2019s disease: beneficial or detrimental effects","volume":"31","author":"Al-Kuraishy","year":"2023","journal-title":"Inflammopharmacology"},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111069_bb0060","first-page":"826","article-title":"Interleukin-2 improves amyloid pathology, synaptic failure and memory in Alzheimer's disease mice","volume":"140","author":"Alves","year":"2017","journal-title":"Brain"},{"issue":"6","key":"10.1016\/j.pnpbp.2024.111069_bb0065","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.neurobiolaging.2009.06.005","article-title":"Endogenous A\u03b2 causes cell death via early tau hyperphosphorylation","volume":"32","author":"Amadoro","year":"2011","journal-title":"Neurobiol. Aging"},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb0070","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/S1474-4422(19)30435-1","article-title":"Interpretation of risk loci from genome-wide association studies of Alzheimer\u2019s disease","volume":"19","author":"Andrews","year":"2020","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111069_bb0075","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/S1474-4422(17)30040-6","article-title":"Effect of long-term omega 3 polyunsaturated fatty acid supplementation with or without multidomain intervention on cognitive function in elderly adults with memory complaints (MAPT): a randomised, placebo-controlled trial","volume":"16","author":"Andrieu","year":"2017","journal-title":"Lancet Neurol."},{"issue":"20","key":"10.1016\/j.pnpbp.2024.111069_bb0080","doi-asserted-by":"crossref","first-page":"4096","DOI":"10.1038\/sj.emboj.7600415","article-title":"RAGE potentiates Abeta-induced perturbation of neuronal function in transgenic mice","volume":"23","author":"Arancio","year":"2004","journal-title":"EMBO J."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2020.102883","article-title":"Brain delivery of supplemental docosahexaenoic acid (DHA): a randomized placebo-controlled clinical trial","volume":"59","author":"Arellanes","year":"2020","journal-title":"EBioMedicine"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0090","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1038\/s41598-018-24501-0","article-title":"Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-beta","volume":"8","author":"Arndt","year":"2018","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0095","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.trci.2015.12.003","article-title":"First in human study with a prodrug of galantamine: improved benefit-risk ratio?","volume":"2","author":"Baakman","year":"2016","journal-title":"Alzheimers Dement. (N Y)"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0100","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1124\/jpet.114.219352","article-title":"Complex disposition of methylthioninium redox forms determines efficacy in tau aggregation inhibitor therapy for Alzheimer\u2019s disease","volume":"352","author":"Baddeley","year":"2015","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0105","article-title":"Safety, pharmacokinetics, and pharmacodynamics of Gln-1062, a prodrug of galantamine","volume":"6","author":"Bakker","year":"2020","journal-title":"Alzheimers Dement. (N Y)"},{"key":"10.1016\/j.pnpbp.2024.111069_bb0110","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.neuroimage.2013.02.059","article-title":"The effects of aging and Alzheimer\u2019s disease on cerebral cortical anatomy: specificity and differential relationships with cognition","volume":"76","author":"Bakkour","year":"2013","journal-title":"Neuroimage"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0115","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s13195-018-0456-x","article-title":"Erlangen score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer\u2019s disease","volume":"11","author":"Baldeiras","year":"2019","journal-title":"Alzheimers Res. Ther."},{"issue":"9","key":"10.1016\/j.pnpbp.2024.111069_bb0120","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa1202753","article-title":"Clinical and biomarker changes in dominantly inherited Alzheimer\u2019s disease","volume":"367","author":"Bateman","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.neurobiolaging.2017.07.001","article-title":"Contribution to Alzheimer\u2019s disease risk of rare variants in TREM2, SORL1, and ABCA7 in 1779 cases and 1273 controls","volume":"59","author":"Bellenguez","year":"2017","journal-title":"Neurobiol. Aging"},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb0130","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1038\/s41588-022-01024-z","article-title":"New insights into the genetic etiology of Alzheimer\u2019s disease and related dementias","volume":"54","author":"Bellenguez","year":"2022","journal-title":"Nat. Genet."},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb0135","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1016\/j.jalz.2016.07.152","article-title":"Systematic evaluation of the associations between environmental risk factors and dementia: An umbrella review of systematic reviews and meta-analyses","volume":"13","author":"Bellou","year":"2017","journal-title":"Alzheimers Dement."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0140","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3233\/JAD-160565","article-title":"Efficacy and safety of plasma exchange with 5% albumin to modify cerebrospinal fluid and plasma amyloid-\u03b2 concentrations and cognition outcomes in Alzheimer\u2019s disease patients: a multicenter, randomized, controlled clinical trial","volume":"56","author":"Boada","year":"2017","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0145","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.trci.2019.01.001","article-title":"Plasma exchange for Alzheimer\u2019s disease management by albumin replacement (AMBAR) trial: study design and progress","volume":"5","author":"Boada","year":"2019","journal-title":"Alzheimers Dement. (N Y)"},{"issue":"9","key":"10.1016\/j.pnpbp.2024.111069_bb0150","first-page":"Cd012820","article-title":"Cannabinoids for the treatment of dementia","volume":"9","author":"Bosnjak Kuharic","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111069_bb0155","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.plefa.2004.07.001","article-title":"Ethyl-EPA in Alzheimer\u2019s disease \u2013 a pilot study","volume":"71","author":"Boston","year":"2004","journal-title":"Prostaglandins Leukot. Essent. Fat. Acids"},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111069_bb0160","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1007\/s00401-022-02418-3","article-title":"Donanemab detects a minor fraction of amyloid-beta plaques in post-mortem brain tissue of patients with Alzheimer\u2019s disease and down syndrome","volume":"143","author":"Bouter","year":"2022","journal-title":"Acta Neuropathol."},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111069_bb0165","doi-asserted-by":"crossref","first-page":"549","DOI":"10.3233\/JAD-141626","article-title":"A clinical study of lupron depot in the treatment of women with Alzheimer\u2019s disease: preservation of cognitive function in patients taking an acetylcholinesterase inhibitor and treated with high dose lupron over 48 weeks","volume":"44","author":"Bowen","year":"2015","journal-title":"J. Alzheimers Dis."},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111069_bb0170","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1007\/s00401-019-02013-z","article-title":"Galectin-3, a novel endogenous TREM2 ligand, detrimentally regulates inflammatory response in Alzheimer\u2019s disease","volume":"138","author":"Boza-Serrano","year":"2019","journal-title":"Acta Neuropathol."},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111069_bb0175","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/acel.12648","article-title":"Dyrk1 inhibition improves Alzheimer\u2019s disease-like pathology","volume":"16","author":"Branca","year":"2017","journal-title":"Aging Cell"},{"issue":"24","key":"10.1016\/j.pnpbp.2024.111069_bb0180","doi-asserted-by":"crossref","DOI":"10.3390\/molecules25245789","article-title":"Comprehensive review on Alzheimer\u2019s disease: causes and treatment","volume":"25","author":"Breijyeh","year":"2020","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0185","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1159\/000498924","article-title":"Prescription of a THC\/CBD-based medication to patients with dementia: a pilot study in Geneva","volume":"2","author":"Broers","year":"2019","journal-title":"Med. Cannabis Cannabinoids"},{"issue":"6","key":"10.1016\/j.pnpbp.2024.111069_bb0190","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1002\/ddr.22085","article-title":"Targeting \u03b17 nicotinic acetylcholine receptors and their protein interactions in Alzheimer\u2019s disease drug development","volume":"84","author":"Burns","year":"2023","journal-title":"Drug Dev. Res."},{"issue":"6","key":"10.1016\/j.pnpbp.2024.111069_bb0195","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jalz.2016.01.012","article-title":"Molecular genetics of early-onset Alzheimer\u2019s disease revisited","volume":"12","author":"Cacace","year":"2016","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0200","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.arr.2017.08.003","article-title":"Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: a systematic review and meta-analysis","volume":"40","author":"Campbell","year":"2017","journal-title":"Ageing Res. Rev."},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb0205","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.3233\/JAD-180263","article-title":"Metformin use associated with reduced risk of dementia in patients with diabetes: a systematic review and Meta-analysis","volume":"65","author":"Campbell","year":"2018","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0210","doi-asserted-by":"crossref","first-page":"1034243","DOI":"10.3389\/fneur.2022.1034243","article-title":"Promising candidates from drug clinical trials: implications for clinical treatment of Alzheimer\u2019s disease in China","volume":"13","author":"Cao","year":"2022","journal-title":"Front. Neurol."},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb0215","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.3233\/JAD-141074","article-title":"Lower brain 18F-fluorodeoxyglucose uptake but normal 11C-acetoacetate metabolism in mild Alzheimer\u2019s disease dementia","volume":"43","author":"Castellano","year":"2015","journal-title":"J. Alzheimers Dis."},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111069_bb0220","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm7009364","article-title":"Multi-target-directed ligands to combat neurodegenerative diseases","volume":"51","author":"Cavalli","year":"2008","journal-title":"J. Med. Chem."},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111069_bb0225","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.3233\/JAD-190864","article-title":"An exploratory phase IIa study of the PPAR delta\/gamma agonist T3D-959 assessing metabolic and cognitive function in subjects with mild to moderate Alzheimer\u2019s disease","volume":"73","author":"Chamberlain","year":"2020","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0230","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41398-020-01137-1","article-title":"Plasma glial fibrillary acidic protein is elevated in cognitively normal older adults at risk of Alzheimer\u2019s disease","volume":"11","author":"Chatterjee","year":"2021","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.pnpbp.2024.111069_bb0235","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.freeradbiomed.2013.03.018","article-title":"Mitochondrial diseases of the brain","volume":"63","author":"Chaturvedi","year":"2013","journal-title":"Free Radic. Biol. Med."},{"issue":"8","key":"10.1016\/j.pnpbp.2024.111069_bb0240","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0024293","article-title":"Allopregnanolone promotes regeneration and reduces \u03b2-amyloid burden in a preclinical model of Alzheimer\u2019s disease","volume":"6","author":"Chen","year":"2011","journal-title":"PLoS One"},{"issue":"8","key":"10.1016\/j.pnpbp.2024.111069_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183586","article-title":"Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: a meta-analysis","volume":"12","author":"Chen","year":"2017","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0250","first-page":"313","article-title":"Alteration of the Wnt\/GSK3\u03b2\/\u03b2-catenin signalling pathway by rapamycin ameliorates pathology in an Alzheimer\u2019s disease model","volume":"44","author":"Chen","year":"2019","journal-title":"Int. J. Mol. Med."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0255","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175439","article-title":"Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases","volume":"938","author":"Chen","year":"2023","journal-title":"Eur. J. Pharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0260","doi-asserted-by":"crossref","first-page":"37","DOI":"10.14336\/AD.2017.1202","article-title":"Metformin and the risk of dementia in type 2 diabetes patients","volume":"10","author":"Chin-Hsiao","year":"2019","journal-title":"Aging Dis."},{"issue":"6","key":"10.1016\/j.pnpbp.2024.111069_bb0265","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1016\/j.pnpbp.2008.05.015","article-title":"The effects of omega-3 fatty acids monotherapy in Alzheimer\u2019s disease and mild cognitive impairment: a preliminary randomized double-blind placebo-controlled study","volume":"32","author":"Chiu","year":"2008","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0270","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/sj.npp.1301559","article-title":"Synaptic plasticity: multiple forms, functions, and mechanisms","volume":"33","author":"Citri","year":"2008","journal-title":"Neuropsychopharmacology"},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111069_bb0275","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1177\/0269881114552744","article-title":"Investigation of the effects of solid lipid curcumin on cognition and mood in a healthy older population","volume":"29","author":"Cox","year":"2015","journal-title":"J. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0280","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archneurol.2011.233","article-title":"Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: a pilot clinical trial","volume":"69","author":"Craft","year":"2012","journal-title":"Arch. Neurol."},{"issue":"16","key":"10.1016\/j.pnpbp.2024.111069_bb0285","doi-asserted-by":"crossref","first-page":"11024","DOI":"10.1074\/jbc.M112.436006","article-title":"Aminothienopyridazines and methylene blue affect tau fibrillization via cysteine oxidation","volume":"288","author":"Crowe","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"7","key":"10.1016\/j.pnpbp.2024.111069_bb0290","article-title":"Biomarkers for Alzheimer\u2019s disease: context of use, qualification, and roadmap for clinical implementation","volume":"58","author":"Cummings","year":"2022","journal-title":"Medicina (Kaunas)"},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111069_bb0295","article-title":"Alzheimer's disease drug development pipeline: 2023","volume":"9","author":"Cummings","year":"2023","journal-title":"Alzheimers Dement. (N Y)"},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb0300","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1016\/j.bcp.2013.12.012","article-title":"Brain metabolic dysfunction at the core of Alzheimer\u2019s disease","volume":"88","author":"de la Monte","year":"2014","journal-title":"Biochem. Pharmacol."},{"issue":"8","key":"10.1016\/j.pnpbp.2024.111069_bb0305","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S1474-4422(22)00234-4","article-title":"The importance of genomics in advancing the diagnosis and treatment of dementia","volume":"21","author":"Decourt","year":"2022","journal-title":"Lancet Neurol."},{"issue":"9","key":"10.1016\/j.pnpbp.2024.111069_bb0310","doi-asserted-by":"crossref","DOI":"10.1002\/gps.6002","article-title":"Effects of lithium on serum brain-derived neurotrophic factor in Alzheimer\u2019s patients with agitation","volume":"38","author":"Deliyannides","year":"2023","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"12","key":"10.1016\/j.pnpbp.2024.111069_bb0315","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.tem.2021.09.004","article-title":"Sex differences in Alzheimer\u2019s disease: metabolic reprogramming and therapeutic intervention","volume":"32","author":"Demetrius","year":"2021","journal-title":"Trends Endocrinol. Metab."},{"issue":"35","key":"10.1016\/j.pnpbp.2024.111069_bb0320","doi-asserted-by":"crossref","first-page":"9057","DOI":"10.1523\/JNEUROSCI.1469-06.2006","article-title":"Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer\u2019s disease brain is associated with mitochondrial dysfunction","volume":"26","author":"Devi","year":"2006","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb0325","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1312889","article-title":"Phase 3 trials of solanezumab for mild-to-moderate Alzheimer\u2019s disease","volume":"370","author":"Doody","year":"2014","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0330","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3233\/JAD-201534","article-title":"Infectious disease Burden and the risk of Alzheimer\u2019s disease: a population-based study","volume":"81","author":"Douros","year":"2021","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0335","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13195-023-01169-x","article-title":"Masitinib for mild-to-moderate Alzheimer\u2019s disease: results from a randomized, placebo-controlled, phase 3, clinical trial","volume":"15","author":"Dubois","year":"2023","journal-title":"Alzheimers Res. Ther."},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111069_bb0340","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3233\/JAD-2010-101161","article-title":"Neuron specific toxicity of oligomeric amyloid-\u03b2: role for JUN-kinase and oxidative stress","volume":"22","author":"Ebenezer","year":"2010","journal-title":"J. Alzheimers Dis."},{"issue":"12","key":"10.1016\/j.pnpbp.2024.111069_bb0345","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jamaneurol.2023.3861","article-title":"Exploratory tau biomarker results from a multiple ascending-dose study of BIIB080 in Alzheimer disease: a randomized clinical trial","volume":"80","author":"Edwards","year":"2023","journal-title":"JAMA Neurol."},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111069_bb0350","doi-asserted-by":"crossref","first-page":"805","DOI":"10.3233\/JAD-150102","article-title":"Plasma fatty acid profiles in relation to cognition and gender in Alzheimer\u2019s disease patients during Oral Omega-3 fatty acid supplementation: the OmegAD study","volume":"48","author":"Eriksdotter","year":"2015","journal-title":"J. Alzheimers Dis."},{"issue":"11","key":"10.1016\/j.pnpbp.2024.111069_bb0355","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1001\/archneur.1997.00550230066019","article-title":"Education and other measures of socioeconomic status and risk of incident Alzheimer disease in a defined population of older persons","volume":"54","author":"Evans","year":"1997","journal-title":"Arch. Neurol."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0360","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1186\/s12974-022-02509-8","article-title":"Semaphorin 4D is upregulated in neurons of diseased brains and triggers astrocyte reactivity","volume":"19","author":"Evans","year":"2022","journal-title":"J. Neuroinflammation"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0365","first-page":"25","article-title":"Buntanetap, a novel translational inhibitor of multiple neurotoxic proteins, proves to be safe and promising in both Alzheimer\u2019s and Parkinson\u2019s patients","volume":"10","author":"Fang","year":"2023","journal-title":"J. Prev Alzheimers Dis."},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb0370","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/hup.2412","article-title":"Comparing the efficacy and safety of Crocus sativus L. with memantine in patients with moderate to severe Alzheimer\u2019s disease: a double-blind randomized clinical trial","volume":"29","author":"Farokhnia","year":"2014","journal-title":"Hum. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0375","doi-asserted-by":"crossref","first-page":"101","DOI":"10.2174\/1570159X13666150716165726","article-title":"Alzheimer\u2019s disease: targeting the cholinergic system","volume":"14","author":"Ferreira-Vieira","year":"2016","journal-title":"Curr. Neuropharmacol."},{"issue":"10","key":"10.1016\/j.pnpbp.2024.111069_bb0380","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s00415-011-6104-z","article-title":"The role of mitochondria in neurodegenerative diseases","volume":"258","author":"Filosto","year":"2011","journal-title":"J. Neurol."},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111069_bb0385","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1021\/acs.jafc.6b04398","article-title":"A perspective on Crocus sativus L. (saffron) constituent Crocin: a potent water-soluble antioxidant and potential therapy for Alzheimer\u2019s disease","volume":"65","author":"Finley","year":"2017","journal-title":"J. Agric. Food Chem."},{"issue":"11","key":"10.1016\/j.pnpbp.2024.111069_bb0390","doi-asserted-by":"crossref","DOI":"10.3390\/biom12111676","article-title":"Linking the amyloid, tau, and mitochondrial hypotheses of Alzheimer\u2019s disease and identifying promising drug targets","volume":"12","author":"Fi\u0161ar","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.pnpbp.2024.111069_bb0395","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.toxlet.2020.12.012","article-title":"Effects of novel 17\u03b2-hydroxysteroid dehydrogenase type 10 inhibitors on mitochondrial respiration","volume":"339","author":"Fi\u0161ar","year":"2021","journal-title":"Toxicol. Lett."},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111069_bb0400","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3233\/JAD-2010-091624","article-title":"Modifiable lifestyle risk factors for Alzheimer\u2019s disease","volume":"20","author":"Flicker","year":"2010","journal-title":"J. Alzheimers Dis."},{"issue":"6","key":"10.1016\/j.pnpbp.2024.111069_bb0405","doi-asserted-by":"crossref","first-page":"2275","DOI":"10.1093\/brain\/awad024","article-title":"Tilavonemab in early Alzheimer\u2019s disease: results from a phase 2, randomized, double-blind study","volume":"146","author":"Florian","year":"2023","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0410","article-title":"Prevention of cognitive decline in subjective cognitive decline APOE \u03b54 carriers after EGCG and a multimodal intervention (PENSA): study design","volume":"7","author":"Forcano","year":"2021","journal-title":"Alzheimers Dement. (N Y)"},{"issue":"11 Suppl 18","key":"10.1016\/j.pnpbp.2024.111069_bb0415","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1017\/S1092852900014164","article-title":"The interplay of neurotransmitters in Alzheimer\u2019s disease","volume":"10","author":"Francis","year":"2005","journal-title":"CNS Spectr."},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111069_bb0420","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1471-4159.1993.tb13381.x","article-title":"Cortical pyramidal neurone loss may cause glutamatergic hypoactivity and cognitive impairment in Alzheimer\u2019s disease: investigative and therapeutic perspectives","volume":"60","author":"Francis","year":"1993","journal-title":"J. Neurochem."},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb0425","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/joim.12166","article-title":"Transfer of omega-3 fatty acids across the blood-brain barrier after dietary supplementation with a docosahexaenoic acid-rich omega-3 fatty acid preparation in patients with Alzheimer\u2019s disease: the OmegAD study","volume":"275","author":"Freund Levi","year":"2014","journal-title":"J. Intern. Med."},{"issue":"10","key":"10.1016\/j.pnpbp.2024.111069_bb0430","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1001\/archneur.63.10.1402","article-title":"Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: a randomized double-blind trial","volume":"63","author":"Freund-Levi","year":"2006","journal-title":"Arch. Neurol."},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111069_bb0435","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/gps.1857","article-title":"Omega-3 supplementation in mild to moderate Alzheimer\u2019s disease: effects on neuropsychiatric symptoms","volume":"23","author":"Freund-Levi","year":"2008","journal-title":"Int. J. Geriatr. Psychiatry"},{"key":"10.1016\/j.pnpbp.2024.111069_bb0440","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.semcdb.2022.07.011","article-title":"The role of genetic risk factors of Alzheimer\u2019s disease in synaptic dysfunction","volume":"139","author":"Fu","year":"2022","journal-title":"Semin. Cell Dev."},{"issue":"12","key":"10.1016\/j.pnpbp.2024.111069_bb0445","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.1007\/s00213-016-4272-3","article-title":"Piromelatine ameliorates memory deficits associated with chronic mild stress-induced anhedonia in rats","volume":"233","author":"Fu","year":"2016","journal-title":"Psychopharmacology"},{"issue":"Suppl. 1","key":"10.1016\/j.pnpbp.2024.111069_bb0450","first-page":"312","article-title":"An essential role for de novo biosynthesis of L-serine in CNS development","volume":"17","author":"Furuya","year":"2008","journal-title":"Asia Pac. J. Clin. Nutr."},{"issue":"7S_Part_5","key":"10.1016\/j.pnpbp.2024.111069_bb0455","doi-asserted-by":"crossref","first-page":"P252","DOI":"10.1016\/j.jalz.2019.06.077","article-title":"P1\u2013052: a single ascending dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-phospho-Tau antibody JNJ-63733657 in healthy subjects","volume":"15","author":"Galpern","year":"2019","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0460","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13024-023-00656-x","article-title":"News & views: anti-amyloid antibodies and novel emerging approaches to Alzheimer's disease in 2023","volume":"18","author":"Gandy","year":"2023","journal-title":"Mol. Neurodegener. England"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0465","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s40035-022-00279-0","article-title":"Brain-derived neurotrophic factor in Alzheimer's disease and its pharmaceutical potential","volume":"11","author":"Gao","year":"2022","journal-title":"Transl. Neurodegener."},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb0470","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1002\/alz.12638","article-title":"2022 Alzheimer\u2019s disease facts and figures","volume":"18","author":"Gaugler","year":"2022","journal-title":"Alzheimers Dement."},{"issue":"10062","key":"10.1016\/j.pnpbp.2024.111069_bb0475","doi-asserted-by":"crossref","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer\u2019s disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial","volume":"388","author":"Gauthier","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pnpbp.2024.111069_bb0480","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2022.117047","article-title":"Guanidine-based \u03b2 amyloid precursor protein cleavage enzyme 1 (BACE-1) inhibitors for the Alzheimer\u2019s disease (AD): a review","volume":"74","author":"Gehlot","year":"2022","journal-title":"Bioorg. Med. Chem."},{"issue":"6","key":"10.1016\/j.pnpbp.2024.111069_bb0485","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1046\/j.1471-4159.1995.65062804.x","article-title":"Protein phosphatase 2A is the major enzyme in brain that dephosphorylates tau protein phosphorylated by proline-directed protein kinases or cyclic AMP-dependent protein kinase","volume":"65","author":"Goedert","year":"1995","journal-title":"J. Neurochem."},{"issue":"3 Suppl","key":"10.1016\/j.pnpbp.2024.111069_bb0490","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3233\/JAD-2006-9S323","article-title":"Tau protein, the paired helical filament and Alzheimer\u2019s disease","volume":"9","author":"Goedert","year":"2006","journal-title":"J. Alzheimers Dis."},{"issue":"10","key":"10.1016\/j.pnpbp.2024.111069_bb0495","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.jalz.2016.02.011","article-title":"O-GlcNAcylation: a regulator of tau pathology and neurodegeneration","volume":"12","author":"Gong","year":"2016","journal-title":"Alzheimers Dement."},{"issue":"10","key":"10.1016\/j.pnpbp.2024.111069_bb0500","first-page":"2481","article-title":"Senolytic therapy to modulate the progression of Alzheimer\u2019s disease (SToMP-AD) - outcomes from the first clinical trial of senolytic therapy for Alzheimer\u2019s disease","volume":"29","author":"Gonzales","year":"2023","journal-title":"Res. Sq."},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111069_bb0505","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1093\/brain\/awac407","article-title":"Brain-derived tau: a novel blood-based biomarker for Alzheimer\u2019s disease-type neurodegeneration","volume":"146","author":"Gonzalez-Ortiz","year":"2023","journal-title":"Brain"},{"key":"10.1016\/j.pnpbp.2024.111069_bb0510","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.neuropharm.2013.11.025","article-title":"Increased O-GlcNAcylation reduces pathological tau without affecting its normal phosphorylation in a mouse model of tauopathy","volume":"79","author":"Graham","year":"2014","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0515","doi-asserted-by":"crossref","first-page":"15779","DOI":"10.1038\/s41598-023-42708-8","article-title":"T cell exhaustion is associated with cognitive status and amyloid accumulation in Alzheimer\u2019s disease","volume":"13","author":"Grayson","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0520","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.semcdb.2022.05.028","article-title":"Synapse pathology in Alzheimer\u2019s disease","volume":"139","author":"Griffiths","year":"2022","journal-title":"Semin. Cell Dev. Biol."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0525","doi-asserted-by":"crossref","first-page":"2261509","DOI":"10.1080\/19420862.2023.2261509","article-title":"Delivery of the BrainshuttleTM amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans","volume":"15","author":"Grimm","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.pnpbp.2024.111069_bb0530","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.trci.2018.11.001","article-title":"A phase 1 clinical trial of the sigma-2 receptor complex allosteric antagonist CT1812, a novel therapeutic candidate for Alzheimer\u2019s disease","volume":"5","author":"Grundman","year":"2019","journal-title":"Alzheimers Dement. (N Y)"},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111069_bb0535","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa1211851","article-title":"TREM2 variants in Alzheimer\u2019s disease","volume":"368","author":"Guerreiro","year":"2013","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111069_bb0540","doi-asserted-by":"crossref","DOI":"10.3390\/cells9020471","article-title":"CD38 in neurodegeneration and Neuroinflammation","volume":"9","author":"Guerreiro","year":"2020","journal-title":"Cells"},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111069_bb0545","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1007\/s11064-022-03782-y","article-title":"Edaravone attenuates A\u03b2 1-42-induced inflammatory damage and Ferroptosis in HT22 cells","volume":"48","author":"Guo","year":"2023","journal-title":"Neurochem. Res."},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111069_bb0550","first-page":"37023","article-title":"Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer\u2019s disease: a comprehensive review","volume":"10","author":"Haddad","year":"2022","journal-title":"Health Psychol. Res."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0555","first-page":"189","article-title":"Alpha-lipoic acid as a new treatment option for Alzheimer\u2019s disease \u2013 a 48 months follow-up analysis","volume":"72","author":"Hager","year":"2007","journal-title":"J. Neural Transm. Suppl."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0560","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jalz.2007.08.006","article-title":"Core candidate neurochemical and imaging biomarkers of Alzheimer\u2019s disease","volume":"4","author":"Hampel","year":"2008","journal-title":"Alzheimers Dement."},{"issue":"6","key":"10.1016\/j.pnpbp.2024.111069_bb0565","doi-asserted-by":"crossref","first-page":"922","DOI":"10.4088\/JCP.08m04606","article-title":"Lithium trial in Alzheimer\u2019s disease: a randomized, single-blind, placebo-controlled, multicenter 10-week study","volume":"70","author":"Hampel","year":"2009","journal-title":"J. Clin. Psychiatry"},{"issue":"7","key":"10.1016\/j.pnpbp.2024.111069_bb0570","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1093\/brain\/awy132","article-title":"The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease","volume":"141","author":"Hampel","year":"2018","journal-title":"Brain"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0575","article-title":"A precision medicine framework using artificial intelligence for the identification and confirmation of genomic biomarkers of response to an Alzheimer\u2019s disease therapy: analysis of the blarcamesine (ANAVEX2-73) phase 2a clinical study","volume":"6","author":"Hampel","year":"2020","journal-title":"Alzheimers Dement. (N Y)"},{"issue":"9","key":"10.1016\/j.pnpbp.2024.111069_bb0580","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41582-021-00520-w","article-title":"Developing the ATX(N) classification for use across the Alzheimer disease continuum","volume":"17","author":"Hampel","year":"2021","journal-title":"Nat. Rev. Neurol."},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111069_bb0585","doi-asserted-by":"crossref","first-page":"703","DOI":"10.3233\/JAD-221231","article-title":"The impact of routine vaccinations on Alzheimer\u2019s disease risk in persons 65 years and older: a claims-based cohort study using propensity score matching","volume":"95","author":"Harris","year":"2023","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0590","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.yhbeh.2013.04.009","article-title":"A novel melatonin agonist Neu-P11 facilitates memory performance and improves cognitive impairment in a rat model of Alzheimer\u2019 disease","volume":"64","author":"He","year":"2013","journal-title":"Horm. Behav."},{"issue":"8","key":"10.1016\/j.pnpbp.2024.111069_bb0595","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1111\/j.1468-1331.2008.02157.x","article-title":"An open-label trial of Korean red ginseng as an adjuvant treatment for cognitive impairment in patients with Alzheimer\u2019s disease","volume":"15","author":"Heo","year":"2008","journal-title":"Eur. J. Neurol."},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb0600","doi-asserted-by":"crossref","first-page":"457","DOI":"10.5142\/jgr.2011.35.4.457","article-title":"Improvement of cognitive deficit in Alzheimer\u2019s disease patients by long term treatment with korean red ginseng","volume":"35","author":"Heo","year":"2011","journal-title":"J. Ginseng Res."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0605","article-title":"Effects of rich cannabidiol oil on behavioral disturbances in patients with dementia: a placebo controlled randomized clinical trial","volume":"9","author":"Hermush","year":"2022","journal-title":"Front. Med. (Lausanne)"},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111069_bb0610","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1002\/alz.12035","article-title":"Polysomnographic assessment of suvorexant in patients with probable Alzheimer\u2019s disease dementia and insomnia: a randomized trial","volume":"16","author":"Herring","year":"2020","journal-title":"Alzheimers Dement."},{"issue":"11","key":"10.1016\/j.pnpbp.2024.111069_bb0615","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.jagp.2019.05.002","article-title":"Randomized placebo-controlled trial of Nabilone for agitation in Alzheimer\u2019s disease","volume":"27","author":"Herrmann","year":"2019","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bib1563","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1186\/s13063-022-06190-3","article-title":"Noradrenergic add-on therapy with extended-release guanfacine in alzheimer\u2019s disease (NorAD): study protocol for a randomised clinical trial and COVID-19 amendments","volume":"23","author":"Hoang","year":"2022","journal-title":"Trials"},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb0620","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1056\/NEJMoa1705971","article-title":"Trial of Solanezumab for mild dementia due to Alzheimer\u2019s disease","volume":"378","author":"Honig","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0625","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/175062","article-title":"Mitochondrial dysfunctions in neurodegenerative diseases: Relevance to alzheimer\u2019s disease","volume":"2014","author":"Hroudov\u00e1","year":"2014","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0630","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/j.ejmech.2016.03.084","article-title":"Progress in drug development for Alzheimer\u2019s disease: An overview in relation to mitochondrial energy metabolism","volume":"121","author":"Hroudova","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0635","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1186\/s12929-023-00976-6","article-title":"Clinical trials of new drugs for Alzheimer disease: a 2020-2023 update","volume":"30","author":"Huang","year":"2023","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0640","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.neuroimage.2018.03.023","article-title":"Effects of resveratrol on memory performance, hippocampus connectivity and microstructure in older adults - a randomized controlled trial","volume":"174","author":"Huhn","year":"2018","journal-title":"Neuroimage"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0645","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s40261-015-0336-0","article-title":"Guanfacine extended release: a new pharmacological treatment option in Europe","volume":"36","author":"Huss","year":"2016","journal-title":"Clin. Drug Investig."},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111069_bb0650","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1532-5415.2012.03916.x","article-title":"Metformin, other antidiabetic drugs, and risk of Alzheimer\u2019s disease: a population-based case-control study","volume":"60","author":"Imfeld","year":"2012","journal-title":"J. Am. Geriatr. Soc."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0655","doi-asserted-by":"crossref","DOI":"10.1016\/j.expneurol.2023.114545","article-title":"Low dose of levetiracetam counteracts amyloid \u03b2-induced alterations of hippocampal gamma oscillations by restoring fast-spiking interneuron activity","volume":"369","author":"Isla","year":"2023","journal-title":"Exp. Neurol."},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111069_bb0660","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","article-title":"Tracking pathophysiological processes in Alzheimer\u2019s disease: an updated hypothetical model of dynamic biomarkers","volume":"12","author":"Jack","year":"2013","journal-title":"Lancet Neurol."},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111069_bb0665","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1212\/WNL.0000000000002923","article-title":"A\/T\/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers","volume":"87","author":"Jack","year":"2016","journal-title":"Neurology"},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb0670","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/j.jalz.2018.02.018","article-title":"NIA-AA research framework: toward a biological definition of Alzheimer\u2019s disease","volume":"14","author":"Jack","year":"2018","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0675","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102012","article-title":"Efficacy and safety of anti-amyloid-\u03b2 monoclonal antibodies in current Alzheimer\u2019s disease phase III clinical trials: a systematic review and interactive web app-based meta-analysis","volume":"90","author":"Jeremic","year":"2023","journal-title":"Ageing Res. Rev."},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111069_bb0680","doi-asserted-by":"crossref","DOI":"10.1002\/brb3.1606","article-title":"A meta-analysis of the effectiveness of Yangxue Qingnao granules for the treatment of chronic cerebral circulation insufficiency","volume":"10","author":"Jia","year":"2020","journal-title":"Brain Behav."},{"issue":"14","key":"10.1016\/j.pnpbp.2024.111069_bb0685","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1073\/pnas.1017033108","article-title":"Soluble amyloid beta-protein dimers isolated from Alzheimer cortex directly induce tau hyperphosphorylation and neuritic degeneration","volume":"108","author":"Jin","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb0690","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/acn3.754","article-title":"Repurposing the KCa3.1 inhibitor senicapoc for Alzheimer\u2019s disease","volume":"6","author":"Jin","year":"2019","journal-title":"Ann. Clin. Transl. Neurol."},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111069_bb0695","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s13311-022-01325-5","article-title":"Fosgonimeton, a novel positive modulator of the HGF\/MET system, promotes neurotrophic and Procognitive effects in models of dementia","volume":"20","author":"Johnston","year":"2023","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.pnpbp.2024.111069_bb0700","doi-asserted-by":"crossref","DOI":"10.1002\/alz.047266","article-title":"AR1001 ameliorates Alzheimer\u2019s disease pathology and symptoms by multi-mechanisms: developing topics","volume":"16","author":"Kang","year":"2020","journal-title":"Alzheimers Dement."},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111069_bb0705","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/S1474-4422(10)70277-5","article-title":"Disrupted energy metabolism and neuronal circuit dysfunction in cognitive impairment and Alzheimer\u2019s disease","volume":"10","author":"Kapogiannis","year":"2011","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.pnpbp.2024.111069_bib1561","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.brainres.2016.01.053","article-title":"Guanfacine promotes neuronal survival in medial prefrontal cortex under hypobaric hypoxia","volume":"1636","author":"Kauser","year":"2016","journal-title":"Brain Res."},{"issue":"13","key":"10.1016\/j.pnpbp.2024.111069_bb0710","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1007\/s40265-023-01922-4","article-title":"Sovateltide: First Approval","volume":"83","author":"Keam","year":"2023","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.pnpbp.2024.111069_bb0715","doi-asserted-by":"crossref","DOI":"10.1002\/bies.201900195","article-title":"Trehalose against Alzheimer\u2019s disease: insights into a potential therapy","volume":"42","author":"Khalifeh","year":"2020","journal-title":"Bioessays"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0720","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s12868-021-00651-2","article-title":"Five-year outcomes after IVIG for mild cognitive impairment due to alzheimer disease","volume":"22","author":"Kile","year":"2021","journal-title":"BMC Neurosci."},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111069_bb0725","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.jgr.2022.09.008","article-title":"Proteomic analysis for the effects of non-saponin fraction with rich polysaccharide from Korean red ginseng on Alzheimer\u2019s disease in a mouse model","volume":"47","author":"Kim","year":"2023","journal-title":"J. Ginseng Res."},{"issue":"9","key":"10.1016\/j.pnpbp.2024.111069_bb0730","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/j.biopsych.2022.10.015","article-title":"Pathogenic role of RAGE in tau transmission and memory deficits","volume":"93","author":"Kim","year":"2023","journal-title":"Biol. Psychiatry"},{"issue":"41","key":"10.1016\/j.pnpbp.2024.111069_bb0735","doi-asserted-by":"crossref","first-page":"38193","DOI":"10.1074\/jbc.M102621200","article-title":"Reduced protein phosphatase 2A activity induces hyperphosphorylation and altered compartmentalization of tau in transgenic mice","volume":"276","author":"Kins","year":"2001","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0740","doi-asserted-by":"crossref","first-page":"105","DOI":"10.3389\/fnins.2017.00105","article-title":"Impact of resveratrol on glucose control, hippocampal structure and connectivity, and memory performance in patients with mild cognitive impairment","volume":"11","author":"K\u00f6be","year":"2017","journal-title":"Front. Neurosci."},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111069_bb0745","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/WAD.0000000000000202","article-title":"Effects of the insulin sensitizer metformin in Alzheimer disease: pilot data from a randomized placebo-controlled crossover study","volume":"31","author":"Koenig","year":"2017","journal-title":"Alzheimer Dis. Assoc. Disord."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0750","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1186\/s13195-021-00803-w","article-title":"Efficacy and safety of GV1001 in patients with moderate-to-severe Alzheimer\u2019s disease already receiving donepezil: a phase 2 randomized, double-blind, placebo-controlled, multicenter clinical trial","volume":"13","author":"Koh","year":"2021","journal-title":"Alzheimers Res. Ther."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0755","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.neuroscience.2017.06.034","article-title":"Newly developed drugs for Alzheimer\u2019s disease in relation to energy metabolism, cholinergic and monoaminergic neurotransmission","volume":"370","author":"Korabecny","year":"2018","journal-title":"Neuroscience"},{"key":"10.1016\/j.pnpbp.2024.111069_bb0760","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/1756-8722-2-36","article-title":"Mechanism of action of lenalidomide in hematological malignancies","volume":"2","author":"Kotla","year":"2009","journal-title":"J. Hematol. Oncol."},{"issue":"Pt B","key":"10.1016\/j.pnpbp.2024.111069_bb0765","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pnpbp.2017.06.002","article-title":"Effects of metformin exposure on neurodegenerative diseases in elderly patients with type 2 diabetes mellitus","volume":"79","author":"Kuan","year":"2017","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111069_bb0770","doi-asserted-by":"crossref","first-page":"713","DOI":"10.3233\/JAD-150886","article-title":"Impact of Omega-3 fatty acid supplementation on memory functions in healthy older adults","volume":"51","author":"K\u00fclzow","year":"2016","journal-title":"J. Alzheimers Dis."},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111069_bb0775","doi-asserted-by":"crossref","first-page":"100","DOI":"10.12779\/dnd.2023.22.3.100","article-title":"Effects of GV1001 on language dysfunction in patients with moderate-to-severe Alzheimer\u2019s disease: post hoc analysis of severe impairment battery subscales","volume":"22","author":"Kwon","year":"2023","journal-title":"Dement. Neurocogn. Disord."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0780","doi-asserted-by":"crossref","DOI":"10.1016\/j.mad.2023.111787","article-title":"Gut-brain axis through the lens of gut microbiota and their relationships with Alzheimer\u2019s disease pathology: review and recommendations","volume":"211","author":"L","year":"2023","journal-title":"Mech. Ageing Dev."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0785","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1186\/s40035-023-00358-w","article-title":"A phase 1b randomized clinical trial of CT1812 to measure A\u03b2 oligomer displacement in Alzheimer\u2019s disease using an indwelling CSF catheter","volume":"12","author":"LaBarbera","year":"2023","journal-title":"Transl. Neurodegener."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0790","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s13195-018-0340-8","article-title":"Safety, tolerability and immunogenicity of an active anti-A\u03b2(40) vaccine (ABvac40) in patients with Alzheimer\u2019s disease: a randomised, double-blind, placebo-controlled, phase I trial","volume":"10","author":"Lacosta","year":"2018","journal-title":"Alzheimers Res. Ther."},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb0795","doi-asserted-by":"crossref","first-page":"315","DOI":"10.3233\/JAD-2003-5407","article-title":"Omega-3 fatty acids and risk of cognitive impairment and dementia","volume":"5","author":"Laurin","year":"2003","journal-title":"J. Alzheimers Dis."},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111069_bb0800","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/WAD.0b013e31816c92e6","article-title":"Panax ginseng enhances cognitive performance in Alzheimer disease","volume":"22","author":"Lee","year":"2008","journal-title":"Alzheimer Dis. Assoc. Disord."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0805","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1007\/s12035-012-8300-y","article-title":"Peripheral mitochondrial dysfunction in Alzheimer\u2019s disease: focus on lymphocytes","volume":"46","author":"Leuner","year":"2012","journal-title":"Mol. Neurobiol."},{"issue":"8","key":"10.1016\/j.pnpbp.2024.111069_bb0810","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41380-018-0342-8","article-title":"Tau PET imaging in neurodegenerative tauopathies-still a challenge","volume":"24","author":"Leuzy","year":"2019","journal-title":"Mol. Psychiatry"},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111069_bb0815","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3233\/JAD-2009-1004","article-title":"Increase of BDNF serum concentration in lithium treated patients with early Alzheimer\u2019s disease","volume":"16","author":"Leyhe","year":"2009","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0820","doi-asserted-by":"crossref","first-page":"27","DOI":"10.2174\/138161212798919075","article-title":"Resveratrol, a neuroprotective supplement for Alzheimer\u2019s disease","volume":"18","author":"Li","year":"2012","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0825","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.ejpb.2022.11.022","article-title":"Modeling digestion, absorption, and ketogenesis after administration of tricaprilin formulations to humans","volume":"182","author":"Li","year":"2023","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0830","article-title":"The role of NLRP3 Inflammasome in Alzheimer\u2019s disease and potential therapeutic targets","volume":"13","author":"Liang","year":"2022","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0835","doi-asserted-by":"crossref","DOI":"10.3389\/fnut.2021.747284","article-title":"The ketogenic effect of medium-chain Triacylglycerides","volume":"8","author":"Lin","year":"2021","journal-title":"Front. Nutr."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0840","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.bbi.2021.10.014","article-title":"Omega-3 fatty acids and blood-based biomarkers in Alzheimer\u2019s disease and mild cognitive impairment: a randomized placebo-controlled trial","volume":"99","author":"Lin","year":"2022","journal-title":"Brain Behav. Immun."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0845","doi-asserted-by":"crossref","first-page":"6625","DOI":"10.1038\/s41598-023-33674-2","article-title":"Pioglitazone use increases risk of Alzheimer\u2019s disease in patients with type 2 diabetes receiving insulin","volume":"13","author":"Lin","year":"2023","journal-title":"Sci. Rep."},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111069_bb0850","doi-asserted-by":"crossref","first-page":"fcad175","DOI":"10.1093\/braincomms\/fcad175","article-title":"Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer\u2019s disease","volume":"5","author":"Liu","year":"2023","journal-title":"Brain Commun."},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111069_bb0855","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","article-title":"Alzheimer disease: An update on pathobiology and treatment strategies","volume":"179","author":"Long","year":"2019","journal-title":"Cell"},{"key":"10.1016\/j.pnpbp.2024.111069_bb0860","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.888989","article-title":"The role of microglia in Alzheimer\u2019s disease from the perspective of immune inflammation and Iron metabolism","volume":"14","author":"Long","year":"2022","journal-title":"Front. Aging Neurosci."},{"issue":"9919","key":"10.1016\/j.pnpbp.2024.111069_bb0865","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/S0140-6736(13)60630-3","article-title":"Genetics of dementia","volume":"383","author":"Loy","year":"2014","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.pnpbp.2024.111069_bb0870","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1080\/13543784.2022.2095261","article-title":"ALZT-OP1: an experimental combination regimen for the treatment of Alzheimer\u2019s disease","volume":"31","author":"Lozupone","year":"2022","journal-title":"Expert Opin. Investig. Drugs"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0875","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejphar.2008.02.048","article-title":"Adiposity, hyperinsulinemia, diabetes and Alzheimer\u2019s disease: an epidemiological perspective","volume":"585","author":"Luchsinger","year":"2008","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb0880","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1212\/01.wnl.0000172914.08967.dc","article-title":"Aggregation of vascular risk factors and risk of incident Alzheimer disease","volume":"65","author":"Luchsinger","year":"2005","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111069_bb0885","doi-asserted-by":"crossref","first-page":"501","DOI":"10.3233\/JAD-150493","article-title":"Metformin in amnestic mild cognitive impairment: results of a pilot randomized placebo controlled clinical trial","volume":"51","author":"Luchsinger","year":"2016","journal-title":"J. Alzheimers Dis."},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111069_bb0890","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.trci.2015.08.002","article-title":"A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects","volume":"1","author":"Lues","year":"2015","journal-title":"Alzheimers Dement. (N Y)"},{"issue":"13","key":"10.1016\/j.pnpbp.2024.111069_bb0895","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1093\/hmg\/ddr139","article-title":"Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer\u2019s disease: implications for neuronal damage","volume":"20","author":"Manczak","year":"2011","journal-title":"Hum. Mol. Genet."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0900","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S0891-5849(96)00629-6","article-title":"Oxidative stress hypothesis in Alzheimer\u2019s disease","volume":"23","author":"Markesbery","year":"1997","journal-title":"Free Radic. Biol. Med."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0905","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/s13024-019-0325-5","article-title":"Neuroimaging biomarkers for Alzheimer\u2019s disease","volume":"14","author":"M\u00e1rquez","year":"2019","journal-title":"Mol. Neurodegener."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0910","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.arr.2012.06.003","article-title":"Tau protein kinases: involvement in Alzheimer\u2019s disease","volume":"12","author":"Martin","year":"2013","journal-title":"Ageing Res. Rev."},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb0915","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S0531-5565(00)00115-7","article-title":"Emerging neuroprotective strategies for Alzheimer\u2019s disease: dietary restriction, telomerase activation, and stem cell therapy","volume":"35","author":"Mattson","year":"2000","journal-title":"Exp. Gerontol."},{"issue":"7\u20138","key":"10.1016\/j.pnpbp.2024.111069_bb0920","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1080\/14789450.2020.1831388","article-title":"The role of synaptic biomarkers in the spectrum of neurodegenerative diseases","volume":"17","author":"Mazzucchi","year":"2020","journal-title":"Expert. Rev. Proteom."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0925","doi-asserted-by":"crossref","first-page":"1129036","DOI":"10.3389\/fnsyn.2023.1129036","article-title":"Alzheimer\u2019s disease as a synaptopathy: evidence for dysfunction of synapses during disease progression","volume":"15","author":"Meftah","year":"2023","journal-title":"Front. Synaptic Neurosci."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0930","doi-asserted-by":"crossref","first-page":"59","DOI":"10.3389\/fnint.2013.00059","article-title":"Inflammatory process in Alzheimer\u2019s disease","volume":"7","author":"Meraz-R\u00edos","year":"2013","journal-title":"Front. Integr. Neurosci."},{"issue":"s1","key":"10.1016\/j.pnpbp.2024.111069_bb0935","doi-asserted-by":"crossref","first-page":"S37","DOI":"10.3233\/JAD-201178","article-title":"Alzheimer\u2019s disease, neural plasticity, and functional recovery","volume":"82","author":"Merceron-Martinez","year":"2021","journal-title":"J. Alzheimers Dis."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0940","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1749-6632.2000.tb05559.x","article-title":"A plasticity-based theory of the pathogenesis of Alzheimer\u2019s disease","volume":"924","author":"Mesulam","year":"2000","journal-title":"Ann. N. Y. Acad. Sci."},{"issue":"6","key":"10.1016\/j.pnpbp.2024.111069_bb0945","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1111\/j.1471-4159.2005.03155.x","article-title":"A biochemical and functional characterization of diet-induced brain insulin resistance","volume":"93","author":"Mielke","year":"2005","journal-title":"J. Neurochem."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0950","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.neuroscience.2013.07.014","article-title":"Attenuating Abeta1-42-induced toxicity by a novel acetylcholinesterase inhibitor","volume":"250","author":"Mishra","year":"2013","journal-title":"Neuroscience"},{"issue":"14","key":"10.1016\/j.pnpbp.2024.111069_bb0955","doi-asserted-by":"crossref","first-page":"e1391","DOI":"10.1212\/WNL.0000000000207663","article-title":"Randomized phase II study of the safety and efficacy of Semorinemab in participants with mild-to-moderate Alzheimer disease: Lauriet","volume":"101","author":"Monteiro","year":"2023","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111069_bb0960","doi-asserted-by":"crossref","first-page":"451","DOI":"10.3233\/JAD-170354","article-title":"The natural product curcumin as a potential coadjuvant in Alzheimer\u2019s treatment","volume":"60","author":"Morales","year":"2017","journal-title":"J. Alzheimers Dis."},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111069_bb0965","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3233\/JAD-131535","article-title":"Glutaminyl cyclase in human cortex: correlation with (pGlu)-amyloid-\u03b2 load and cognitive decline in Alzheimer\u2019s disease","volume":"39","author":"Morawski","year":"2014","journal-title":"J. Alzheimers Dis."},{"issue":"12","key":"10.1016\/j.pnpbp.2024.111069_bb0970","doi-asserted-by":"crossref","first-page":"1936","DOI":"10.1016\/j.biocel.2010.08.020","article-title":"Mitochondrial regulation of insulin action","volume":"42","author":"Murrow","year":"2010","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.pnpbp.2024.111069_bb0975","first-page":"43","article-title":"Alzheimer\u2019s disease puzzle: delving into pathogenesis hypotheses","volume":"1","author":"Nasb","year":"2023","journal-title":"Aging Dis.15"},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111069_bb0980","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1212\/WNL.0b013e31823efcbb","article-title":"Nicotine treatment of mild cognitive impairment: a 6-month double-blind pilot clinical trial","volume":"78","author":"Newhouse","year":"2012","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111069_bb0985","doi-asserted-by":"crossref","DOI":"10.3390\/biom11020195","article-title":"Epigenetics of Alzheimer\u2019s disease","volume":"11","author":"Nikolac Perkovic","year":"2021","journal-title":"Biomolecules"},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111069_bb0990","doi-asserted-by":"crossref","first-page":"83","DOI":"10.15280\/jlm.2023.13.2.83","article-title":"Effect of daily coffee consumption on the risk of Alzheimer\u2019s disease: a systematic review and Meta-analysis","volume":"13","author":"Nila","year":"2023","journal-title":"J. Lifestyle Med."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb0995","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1097\/FBP.0000000000000414","article-title":"SUVN-502, a novel, potent, pure, and orally active 5-HT6 receptor antagonist: pharmacological, behavioral, and neurochemical characterization","volume":"30","author":"Nirogi","year":"2019","journal-title":"Behav. Pharmacol."},{"issue":"10","key":"10.1016\/j.pnpbp.2024.111069_bb1000","doi-asserted-by":"crossref","DOI":"10.1002\/gps.5813","article-title":"Potential beneficial effects of masupirdine (SUVN-502) on agitation\/aggression and psychosis in patients with moderate Alzheimer\u2019s disease: exploratory post hoc analyses","volume":"37","author":"Nirogi","year":"2022","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111069_bb1005","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1080\/15548627.2021.1909409","article-title":"Targeting autophagy as a therapeutic strategy to prevent dopamine neuron loss in early stages of Alzheimer disease","volume":"17","author":"Nobili","year":"2021","journal-title":"Autophagy"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb1010","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13195-021-00788-6","article-title":"Melatonin levels in the Alzheimer's disease continuum: a systematic review","volume":"13","author":"Nous","year":"2021","journal-title":"Alzheimers Res. Ther."},{"issue":"6","key":"10.1016\/j.pnpbp.2024.111069_bb1015","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/s43587-021-00070-2","article-title":"ADAMANT: a placebo-controlled randomized phase 2 study of AADvac1, an active immunotherapy against pathological tau in Alzheimer's disease","volume":"1","author":"Novak","year":"2021","journal-title":"Nat. Aging"},{"key":"10.1016\/j.pnpbp.2024.111069_bb1020","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.dadm.2016.06.004","article-title":"A blood screening test for Alzheimer\u2019s disease","volume":"3","author":"O\u2019Bryant","year":"2016","journal-title":"Alzheimers Dement. (Amst.)"},{"key":"10.1016\/j.pnpbp.2024.111069_bb1025","doi-asserted-by":"crossref","first-page":"29","DOI":"10.2147\/CIA.S95362","article-title":"Benefits of use, and tolerance of, medium-chain triglyceride medical food in the management of Japanese patients with Alzheimer\u2019s disease: a prospective, open-label pilot study","volume":"11","author":"Ohnuma","year":"2016","journal-title":"Clin. Interv. Aging"},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb1030","first-page":"401","article-title":"The oxidative stress hypothesis in Alzheimer\u2019s disease","volume":"25","author":"Padurariu","year":"2013","journal-title":"Psychiatr. Danub."},{"key":"10.1016\/j.pnpbp.2024.111069_bb1035","doi-asserted-by":"crossref","first-page":"3245935","DOI":"10.1155\/2016\/3245935","article-title":"Tau-centric targets and drugs in clinical development for the treatment of Alzheimer\u2019s disease","volume":"2016","author":"Panza","year":"2016","journal-title":"Biomed. Res. Int."},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111069_bb1040","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/s41582-018-0116-6","article-title":"A critical appraisal of amyloid-\u03b2-targeting therapies for Alzheimer disease","volume":"15","author":"Panza","year":"2019","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.pnpbp.2024.111069_bb1045","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/B978-0-323-98817-9.00029-6","article-title":"Passive tau-based immunotherapy for tauopathies","volume":"196","author":"Panza","year":"2023","journal-title":"Handb. Clin. Neurol."},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb1050","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3988\/jcn.2022.18.4.401","article-title":"Promising blood biomarkers for clinical use in Alzheimer\u2019s disease: a focused update","volume":"18","author":"Park","year":"2022","journal-title":"J. Clin. Neurol."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb1055","doi-asserted-by":"crossref","DOI":"10.1002\/pep2.24289","article-title":"Current peptide vaccine and immunotherapy approaches against Alzheimer\u2019s disease","volume":"115","author":"Parrocha","year":"2023","journal-title":"Pept. Sci."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb1060","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3233\/ADR-220021","article-title":"Emerging pathophysiological mechanisms linking diabetes mellitus and Alzheimer\u2019s disease: An old wine in a new bottle","volume":"6","author":"Patel","year":"2022","journal-title":"J. Alzheimers Dis. Rep."},{"key":"10.1016\/j.pnpbp.2024.111069_bb1065","doi-asserted-by":"crossref","DOI":"10.3389\/fnagi.2022.957665","article-title":"Cannabinoids for behavioral symptoms in severe dementia: safety and feasibility in a long-term pilot observational study in nineteen patients","volume":"14","author":"Pautex","year":"2022","journal-title":"Front. Aging Neurosci."},{"issue":"1\u20133","key":"10.1016\/j.pnpbp.2024.111069_bb1070","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0014-2999(00)00064-9","article-title":"Nicotinic receptor subtypes in human brain ageing, Alzheimer and Lewy body diseases","volume":"393","author":"Perry","year":"2000","journal-title":"Eur. J. Pharmacol."},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111069_bb1075","first-page":"201","article-title":"Diminished glucose transport and phosphorylation in Alzheimer\u2019s disease determined by dynamic FDG-PET","volume":"37","author":"Piert","year":"1996","journal-title":"J. Nucl. Med."},{"key":"10.1016\/j.pnpbp.2024.111069_bb1080","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.pnpbp.2013.12.001","article-title":"GSK3beta, CREB, and BDNF in peripheral blood of patients with Alzheimer's disease and depression","volume":"50","author":"Platenik","year":"2014","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb1085","article-title":"Safety and efficacy of sargramostim (GM-CSF) in the treatment of Alzheimer\u2019s disease","volume":"7","author":"Potter","year":"2021","journal-title":"Alzheimers Dement. (N Y)"},{"issue":"17","key":"10.1016\/j.pnpbp.2024.111069_bb1090","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.2010.1510","article-title":"Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: a randomized trial","volume":"304","author":"Quinn","year":"2010","journal-title":"JAMA"},{"issue":"16","key":"10.1016\/j.pnpbp.2024.111069_bb1095","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1212\/WNL.0b013e318216eb7b","article-title":"A phase II trial of huperzine A in mild to moderate Alzheimer disease","volume":"76","author":"Rafii","year":"2011","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb1100","article-title":"Exploratory imaging outcomes of a phase 1b\/2a clinical trial of allopregnanolone as a regenerative therapeutic for Alzheimer\u2019s disease: structural effects and functional connectivity outcomes","volume":"8","author":"Raikes","year":"2022","journal-title":"Alzheimers Dement. (N Y)"},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111069_bb1105","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1590\/1980-57642020dn14-030004","article-title":"Genetics of dementia: insights from Latin America","volume":"14","author":"Ramos","year":"2020","journal-title":"Dement. Neuropsychol."},{"key":"10.1016\/j.pnpbp.2024.111069_bb1110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.ebiom.2018.01.021","article-title":"Traumatic brain injury and Alzheimer\u2019s disease: the cerebrovascular link","volume":"28","author":"Ramos-Cejudo","year":"2018","journal-title":"EBioMedicine"},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb1115","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2217\/nmt-2021-0022","article-title":"NM101 phase III study of NE3107 in Alzheimer\u2019s disease: rationale, design and therapeutic modulation of neuroinflammation and insulin resistance","volume":"11","author":"Reading","year":"2021","journal-title":"Neurodegener. Dis. Manag."},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb1120","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines11041131","article-title":"RAGE inhibitors in neurodegenerative diseases","volume":"11","author":"Reddy","year":"2023","journal-title":"Biomedicines"},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111069_bb1125","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0197-4580(03)00087-3","article-title":"Effects of beta-hydroxybutyrate on cognition in memory-impaired adults","volume":"25","author":"Reger","year":"2004","journal-title":"Neurobiol. Aging"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb1130","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1503\/jpn.110190","article-title":"Glutamate system, amyloid \u00df peptides and tau protein: functional interrelationships and relevance to Alzheimer disease pathology","volume":"38","author":"Revett","year":"2013","journal-title":"J. Psychiatry Neurosci."},{"issue":"38","key":"10.1016\/j.pnpbp.2024.111069_bb1135","doi-asserted-by":"crossref","first-page":"8807","DOI":"10.1523\/JNEUROSCI.1521-05.2005","article-title":"Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice","volume":"25","author":"Rezai-Zadeh","year":"2005","journal-title":"J. Neurosci."},{"issue":"6\u20137","key":"10.1016\/j.pnpbp.2024.111069_bb1140","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s10571-009-9398-y","article-title":"Amyloid-beta leads to impaired cellular respiration, energy production and mitochondrial electron chain complex activities in human neuroblastoma cells","volume":"29","author":"Rhein","year":"2009","journal-title":"Cell. Mol. Neurobiol."},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111069_bb1145","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1186\/alzrt146","article-title":"Oral curcumin for Alzheimer\u2019s disease: tolerability and efficacy in a 24-week randomized, double blind, placebo-controlled study","volume":"4","author":"Ringman","year":"2012","journal-title":"Alzheimers Res. Ther."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb1150","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/s40478-020-0884-2","article-title":"Pre-clinical characterisation of E2814, a high-affinity antibody targeting the microtubule-binding repeat domain of tau for passive immunotherapy in Alzheimer\u2019s disease","volume":"8","author":"Roberts","year":"2020","journal-title":"Acta Neuropathol. Commun."},{"issue":"12","key":"10.1016\/j.pnpbp.2024.111069_bb1155","doi-asserted-by":"crossref","first-page":"3269","DOI":"10.1093\/brain\/awx256","article-title":"Tau hyperphosphorylation induces oligomeric insulin accumulation and insulin resistance in neurons","volume":"140","author":"Rodriguez-Rodriguez","year":"2017","journal-title":"Brain"},{"issue":"36","key":"10.1016\/j.pnpbp.2024.111069_bb1160","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.2174\/138161209789909692","article-title":"Effects of dietary polyunsaturated fatty acids on mitochondria","volume":"15","author":"Rohrbach","year":"2009","journal-title":"Curr. Pharm. Des."},{"issue":"S9","key":"10.1016\/j.pnpbp.2024.111069_bb1165","doi-asserted-by":"crossref","DOI":"10.1002\/alz.045331","article-title":"HOPE4MCI trial: first trial targeting reduction of hippocampal overactivity to treat mild cognitive impairment due to Alzheimer\u2019s disease with AGB101","volume":"16","author":"Rosenzweig-Lipson","year":"2020","journal-title":"Alzheimers Dement."},{"key":"10.1016\/j.pnpbp.2024.111069_bb1170","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.neurobiolaging.2018.06.006","article-title":"An isoform-selective p38\u03b1 mitogen-activated protein kinase inhibitor rescues early entorhinal cortex dysfunctions in a mouse model of Alzheimer\u2019s disease","volume":"70","author":"Rutigliano","year":"2018","journal-title":"Neurobiol. Aging"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb1175","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1001\/jamaneurol.2021.4161","article-title":"Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating Aducanumab in patients with early Alzheimer disease","volume":"79","author":"Salloway","year":"2022","journal-title":"JAMA Neurol."},{"issue":"6","key":"10.1016\/j.pnpbp.2024.111069_bb1180","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.23m14791","article-title":"The use of dispensary-obtained tetrahydrocannabinol as a treatment for neuropsychiatric symptoms of dementia","volume":"84","author":"Sawicki","year":"2023","journal-title":"J. Clin. Psychiatry"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb1185","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1186\/s13195-018-0431-6","article-title":"Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer\u2019s disease: results of a randomized, double-blind, placebo-controlled phase 2a study","volume":"10","author":"Scheltens","year":"2018","journal-title":"Alzheimers Res. Ther."},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111069_bb1190","first-page":"247","article-title":"A polymorphism cluster at the 2q12 locus may predict response to Piromelatine in patients with mild Alzheimer\u2019s disease","volume":"9","author":"Schneider","year":"2022","journal-title":"J. Prev Alzheimers Dis."},{"issue":"6","key":"10.1016\/j.pnpbp.2024.111069_bb1195","doi-asserted-by":"crossref","first-page":"595","DOI":"10.15252\/emmm.201606210","article-title":"The amyloid hypothesis of Alzheimer\u2019s disease at 25 years","volume":"8","author":"Selkoe","year":"2016","journal-title":"EMBO Mol. Med."},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111069_bb1200","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1586\/14737175.2016.1140039","article-title":"Tau-directed approaches for the treatment of Alzheimer\u2019s disease: focus on leuco-methylthioninium","volume":"16","author":"Seripa","year":"2016","journal-title":"Expert. Rev. Neurother."},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111069_bb1205","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1177\/1533317513518650","article-title":"Role of medium chain triglycerides (Axona\u00ae) in the treatment of mild to moderate Alzheimer\u2019s disease","volume":"29","author":"Sharma","year":"2014","journal-title":"Am. J. Alzheimers Dis. Other Dement."},{"issue":"S4","key":"10.1016\/j.pnpbp.2024.111069_bb1210","doi-asserted-by":"crossref","DOI":"10.1002\/alz.040558","article-title":"Brain target occupancy of LY3372689, an inhibitor of the O-GlcNAcase (OGA) enzyme: translation from rat to human","volume":"16","author":"Shcherbinin","year":"2020","journal-title":"Alzheimers Dement."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb1215","doi-asserted-by":"crossref","first-page":"15","DOI":"10.3233\/JAD-150915","article-title":"Safety and efficacy of medical Cannabis oil for behavioral and psychological symptoms of dementia: An-open label, add-on, pilot study","volume":"51","author":"Shelef","year":"2016","journal-title":"J. Alzheimers Dis."},{"issue":"7673","key":"10.1016\/j.pnpbp.2024.111069_bb1220","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/nature24016","article-title":"ApoE4 markedly exacerbates tau-mediated neurodegeneration in a mouse model of tauopathy","volume":"549","author":"Shi","year":"2017","journal-title":"Nature"},{"issue":"7","key":"10.1016\/j.pnpbp.2024.111069_bb1225","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-024954","article-title":"Effect of metformin on neurodegenerative disease among elderly adult US veterans with type 2 diabetes mellitus","volume":"9","author":"Shi","year":"2019","journal-title":"BMJ Open"},{"issue":"12","key":"10.1016\/j.pnpbp.2024.111069_bb1230","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20123030","article-title":"Red ginseng attenuates A\u03b2-induced mitochondrial dysfunction and A\u03b2-mediated pathology in an animal model of Alzheimer\u2019s disease","volume":"20","author":"Shin","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.pnpbp.2024.111069_bb1235","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22063168","article-title":"A state of the art of antioxidant properties of curcuminoids in neurodegenerative diseases","volume":"22","author":"Silvestro","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"8","key":"10.1016\/j.pnpbp.2024.111069_bb1240","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1016\/j.neurobiolaging.2011.06.008","article-title":"Allopregnanolone restores hippocampal-dependent learning and memory and neural progenitor survival in aging 3xTgAD and nonTg mice","volume":"33","author":"Singh","year":"2012","journal-title":"Neurobiol. Aging"},{"key":"10.1016\/j.pnpbp.2024.111069_bb1245","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.nbd.2014.10.008","article-title":"SEMA4D compromises blood-brain barrier, activates microglia, and inhibits remyelination in neurodegenerative disease","volume":"73","author":"Smith","year":"2015","journal-title":"Neurobiol. Dis."},{"issue":"6","key":"10.1016\/j.pnpbp.2024.111069_bb1250","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/BF02536067","article-title":"Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease","volume":"26","author":"S\u00f6derberg","year":"1991","journal-title":"Lipids"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb1255","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1007\/s13311-022-01308-6","article-title":"Lecanemab, Aducanumab, and Gantenerumab - binding profiles to different forms of amyloid-Beta might explain efficacy and side effects in clinical trials for Alzheimer\u2019s disease","volume":"20","author":"Soderberg","year":"2022","journal-title":"Neurotherapeutics."},{"key":"10.1016\/j.pnpbp.2024.111069_bb1260","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2020.590896","article-title":"New insights into drug discovery targeting tau protein","volume":"13","author":"Soeda","year":"2020","journal-title":"Front. Mol. Neurosci."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb1265","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3233\/JAD-2005-7107","article-title":"Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer\u2019s disease \u2013 is this type 3 diabetes?","volume":"7","author":"Steen","year":"2005","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb1270","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1097\/00005072-199901000-00004","article-title":"Pathologic evaluation of the human suprachiasmatic nucleus in severe dementia","volume":"58","author":"Stopa","year":"1999","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"S1","key":"10.1016\/j.pnpbp.2024.111069_bib1567","first-page":"S49","article-title":"Abstract: symposia, conferences, oral communications: 14th clinical trials on Alzheimer\u2019s disease (CTAD)","volume":"8","author":"Streffer","year":"2021","journal-title":"J. Prev. Alzheimers Dis."},{"issue":"Suppl1","key":"10.1016\/j.pnpbp.2024.111069_bib1565","first-page":"S12","article-title":"15th Conference Clinical Trials Alzheimer\u2019s Disease, November 29- December 2, 2022, San Francisco, CA, USA: Symposia - Oral Communications - Late Breaking Abstracts (Clinical Trial Alzheimer\u2019s Disease)","volume":"9","author":"Streffer","year":"2022","journal-title":"J. Prev. Alzheimers Dis."},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111069_bb1275","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15051399","article-title":"Intranasal drug Administration in Alzheimer-Type Dementia: towards clinical applications","volume":"15","author":"Tal\u00e9ns-Visconti","year":"2023","journal-title":"Pharmaceutics"},{"issue":"6","key":"10.1016\/j.pnpbp.2024.111069_bb1280","doi-asserted-by":"crossref","first-page":"2569","DOI":"10.1016\/j.clnu.2018.11.034","article-title":"Probiotic and selenium co-supplementation, and the effects on clinical, metabolic and genetic status in Alzheimer\u2019s disease: a randomized, double-blind, controlled trial","volume":"38","author":"Tamtaji","year":"2019","journal-title":"Clin. Nutr."},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb1285","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.bbrc.2015.08.076","article-title":"Trehalose intake induces chaperone molecules along with autophagy in a mouse model of Lewy body disease","volume":"465","author":"Tanji","year":"2015","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.pnpbp.2024.111069_bb1290","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-056964","article-title":"Safety and efficacy of plasma transfusion from exercise-trained donors in patients with early Alzheimer\u2019s disease: protocol for the ExPlas study","volume":"12","author":"Tari","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.pnpbp.2024.111069_bb1295","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2023.106764","article-title":"Nicotinic acetylcholine receptors in neurological and psychiatric diseases","volume":"191","author":"Terry","year":"2023","journal-title":"Pharmacol. Res."},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111069_bb1300","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/jnr.10441","article-title":"Neuroplasticity in Alzheimer\u2019s disease","volume":"70","author":"Teter","year":"2002","journal-title":"J. Neurosci. Res."},{"issue":"8","key":"10.1016\/j.pnpbp.2024.111069_bb1305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0072301","article-title":"Efficacy and safety of a liposome-based vaccine against protein tau, assessed in tau.P301L mice that model tauopathy","volume":"8","author":"Theunis","year":"2013","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111069_bb1310","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3233\/JAD-210007","article-title":"Effects of Peroral Omega-3 fatty acid supplementation on cerebrospinal fluid biomarkers in patients with Alzheimer\u2019s disease: a randomized controlled trial-the OmegAD study","volume":"83","author":"Tofiq","year":"2021","journal-title":"J. Alzheimers Dis."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb1315","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s13195-020-00663-w","article-title":"Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer\u2019s disease with potential for near term approval","volume":"12","author":"Tolar","year":"2020","journal-title":"Alzheimers Res. Ther."},{"issue":"12","key":"10.1016\/j.pnpbp.2024.111069_bb1320","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126355","article-title":"Neurotoxic soluble amyloid oligomers drive Alzheimer\u2019s pathogenesis and represent a clinically validated target for slowing disease progression","volume":"22","author":"Tolar","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb1325","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3233\/JAD-151013","article-title":"T3D-959: a multi-faceted disease remedial drug candidate for the treatment of Alzheimer\u2019s disease","volume":"51","author":"Tong","year":"2016","journal-title":"J. Alzheimers Dis."},{"issue":"2","key":"10.1016\/j.pnpbp.2024.111069_bb1330","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.apsb.2021.10.002","article-title":"Apolipoprotein E and Alzheimer\u2019s disease","volume":"12","author":"Troutwine","year":"2022","journal-title":"Acta Pharm. Sin. B"},{"issue":"16","key":"10.1016\/j.pnpbp.2024.111069_bb1335","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1212\/WNL.0000000000002035","article-title":"A randomized, double-blind, placebo-controlled trial of resveratrol for Alzheimer disease","volume":"85","author":"Turner","year":"2015","journal-title":"Neurology"},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb1340","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1002\/ana.25775","article-title":"Nilotinib effects on safety, tolerability, and biomarkers in Alzheimer\u2019s disease","volume":"88","author":"Turner","year":"2020","journal-title":"Ann. Neurol."},{"issue":"23","key":"10.1016\/j.pnpbp.2024.111069_bb1345","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1212\/WNL.0000000000001675","article-title":"Tetrahydrocannabinol for neuropsychiatric symptoms in dementia: a randomized controlled trial","volume":"84","author":"van den Elsen","year":"2015","journal-title":"Neurology"},{"issue":"12","key":"10.1016\/j.pnpbp.2024.111069_bb1350","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/j.jagp.2015.07.011","article-title":"Tetrahydrocannabinol in behavioral disturbances in dementia: a crossover randomized controlled trial","volume":"23","author":"van den Elsen","year":"2015","journal-title":"Am. J. Geriatr. Psychiatry"},{"issue":"Suppl. 5","key":"10.1016\/j.pnpbp.2024.111069_bb1355","doi-asserted-by":"crossref","first-page":"v2","DOI":"10.1136\/jnnp.2005.082867","article-title":"Epidemiology and risk factors of dementia","volume":"76","author":"van der Flier","year":"2005","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb1360","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.biopsych.2017.08.010","article-title":"Anti-amyloid-\u03b2 monoclonal antibodies for Alzheimer\u2019s disease: pitfalls and promise","volume":"83","author":"van Dyck","year":"2018","journal-title":"Biol. Psychiatry"},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb1365","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3928\/02793695-20100302-01","article-title":"How neuroplasticity and cognitive reserve protect cognitive functioning","volume":"48","author":"Vance","year":"2010","journal-title":"J. Psychosoc. Nurs. Ment. Health Serv."},{"key":"10.1016\/j.pnpbp.2024.111069_bb1370","doi-asserted-by":"crossref","first-page":"59","DOI":"10.4137\/NMI.S10233","article-title":"Effects of caffeine on metabolism and mitochondria biogenesis in rhabdomyosarcoma cells compared with 2,4-dinitrophenol","volume":"5","author":"Vaughan","year":"2012","journal-title":"Nutr. Metab. Insights"},{"key":"10.1016\/j.pnpbp.2024.111069_bb1375","doi-asserted-by":"crossref","first-page":"797","DOI":"10.2147\/CIA.S325026","article-title":"Role of Aducanumab in the treatment of Alzheimer\u2019s disease: challenges and opportunities","volume":"17","author":"Vaz","year":"2022","journal-title":"Clin. Interv. Aging"},{"issue":"12","key":"10.1016\/j.pnpbp.2024.111069_bb1380","doi-asserted-by":"crossref","first-page":"8364","DOI":"10.1007\/s12035-019-01684-9","article-title":"Chronic Dyrk1 inhibition delays the onset of AD-like pathology in 3xTg-AD mice","volume":"56","author":"Velazquez","year":"2019","journal-title":"Mol. Neurobiol."},{"issue":"8","key":"10.1016\/j.pnpbp.2024.111069_bb1385","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1177\/0269881110379286","article-title":"Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor\/sigma 1 (\u03c31) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative","volume":"25","author":"Villard","year":"2011","journal-title":"J. Psychopharmacol."},{"issue":"9","key":"10.1016\/j.pnpbp.2024.111069_bb1390","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1002\/(SICI)1099-1166(199709)12:9<913::AID-GPS663>3.0.CO;2-D","article-title":"Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer\u2019s disease","volume":"12","author":"Volicer","year":"1997","journal-title":"Int. J. Geriatr. Psychiatry"},{"issue":"11","key":"10.1016\/j.pnpbp.2024.111069_bb1395","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1001\/jamaneurol.2021.3310","article-title":"Effect of Levetiracetam on cognition in patients with Alzheimer disease with and without epileptiform activity: a randomized clinical trial","volume":"78","author":"Vossel","year":"2021","journal-title":"JAMA Neurol."},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111069_bb1400","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1111\/j.1471-4159.2006.04426.x","article-title":"A beta oligomers - a decade of discovery","volume":"101","author":"Walsh","year":"2007","journal-title":"J. Neurochem."},{"issue":"29","key":"10.1016\/j.pnpbp.2024.111069_bb1405","doi-asserted-by":"crossref","first-page":"9773","DOI":"10.1523\/JNEUROSCI.0354-12.2012","article-title":"Reducing amyloid-related Alzheimer\u2019s disease pathogenesis by a small molecule targeting filamin a","volume":"32","author":"Wang","year":"2012","journal-title":"J. Neurosci."},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111069_bb1410","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1021\/pr5000895","article-title":"Plasma metabolite profiles of Alzheimer\u2019s disease and mild cognitive impairment","volume":"13","author":"Wang","year":"2014","journal-title":"J. Proteome Res."},{"issue":"11","key":"10.1016\/j.pnpbp.2024.111069_bb1415","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1038\/nrneurol.2017.147","article-title":"A systemic view of Alzheimer disease - insights from amyloid-\u03b2 metabolism beyond the brain","volume":"13","author":"Wang","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.pnpbp.2024.111069_bb1420","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3389\/fnagi.2017.00157","article-title":"YXQN reduces Alzheimer\u2019s disease-like pathology and cognitive decline in APPswePS1dE9 transgenic mice","volume":"9","author":"Wang","year":"2017","journal-title":"Front. Aging Neurosci."},{"issue":"4","key":"10.1016\/j.pnpbp.2024.111069_bb1425","first-page":"256","article-title":"PTI-125 reduces biomarkers of Alzheimer\u2019s disease in patients","volume":"7","author":"Wang","year":"2020","journal-title":"J. Prev Alzheimers Dis."},{"issue":"9","key":"10.1016\/j.pnpbp.2024.111069_bb1430","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200785","article-title":"Anti-human TREM2 induces microglia proliferation and reduces pathology in an Alzheimer\u2019s disease model","volume":"217","author":"Wang","year":"2020","journal-title":"J. Exp. Med."},{"issue":"18","key":"10.1016\/j.pnpbp.2024.111069_bb1435","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241813927","article-title":"Simufilam reverses aberrant receptor interactions of Filamin a in Alzheimer\u2019s disease","volume":"24","author":"Wang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pnpbp.2024.111069_bb1440","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109706","article-title":"Hydralazine inhibits neuroinflammation and oxidative stress in APP\/PS1 mice via TLR4\/NF-\u03baB and Nrf2 pathways","volume":"240","author":"Wang","year":"2023","journal-title":"Neuropharmacology"},{"issue":"10","key":"10.1016\/j.pnpbp.2024.111069_bb1445","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/S1474-4422(14)70117-6","article-title":"The role of iron in brain ageing and neurodegenerative disorders","volume":"13","author":"Ward","year":"2014","journal-title":"Lancet Neurol."},{"issue":"12","key":"10.1016\/j.pnpbp.2024.111069_bb1450","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1212\/01.WNL.0000065916.25128.25","article-title":"Insulin increases CSF Abeta42 levels in normal older adults","volume":"60","author":"Watson","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.pnpbp.2024.111069_bb1455","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2021.687157","article-title":"Insulin resistance exacerbates Alzheimer disease via multiple mechanisms","volume":"15","author":"Wei","year":"2021","journal-title":"Front. Neurosci."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb1460","article-title":"VALZ-pilot: high-dose valacyclovir treatment in patients with early-stage Alzheimer\u2019s disease","volume":"8","author":"Weidung","year":"2022","journal-title":"Alzheimers Dement. (N Y)"},{"issue":"23","key":"10.1016\/j.pnpbp.2024.111069_bb1465","doi-asserted-by":"crossref","first-page":"7862","DOI":"10.1523\/JNEUROSCI.0385-14.2014","article-title":"Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults","volume":"34","author":"Witte","year":"2014","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb1470","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20010081","article-title":"The role of APOE and TREM2 in Alzheimer\u2019s disease-current understanding and perspectives","volume":"20","author":"Wolfe","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.pnpbp.2024.111069_bb1475","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/363985","article-title":"Huperzine a in the treatment of Alzheimer\u2019s disease and vascular dementia: a meta-analysis","volume":"2014","author":"Xing","year":"2014","journal-title":"Evid. Based Complement. Alternat. Med."},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111069_bb1480","first-page":"391","article-title":"Efficacy of tablet huperzine-A on memory, cognition, and behavior in Alzheimer\u2019s disease","volume":"16","author":"Xu","year":"1995","journal-title":"Zhongguo Yao Li Xue Bao"},{"issue":"6","key":"10.1016\/j.pnpbp.2024.111069_bb1485","first-page":"486","article-title":"Huperzine-a in capsules and tablets for treating patients with Alzheimer disease","volume":"20","author":"Xu","year":"1999","journal-title":"Zhongguo Yao Li Xue Bao"},{"issue":"7","key":"10.1016\/j.pnpbp.2024.111069_bb1490","doi-asserted-by":"crossref","first-page":"5892","DOI":"10.1074\/jbc.M404751200","article-title":"Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo","volume":"280","author":"Yang","year":"2005","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb1495","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1523\/JNEUROSCI.1698-16.2016","article-title":"Large soluble oligomers of amyloid beta-protein from Alzheimer brain are far less neuroactive than the smaller oligomers to which they dissociate","volume":"37","author":"Yang","year":"2017","journal-title":"J. Neurosci."},{"issue":"7903","key":"10.1016\/j.pnpbp.2024.111069_bb1500","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1038\/s41586-021-04369-3","article-title":"A human brain vascular atlas reveals diverse mediators of Alzheimer\u2019s risk","volume":"603","author":"Yang","year":"2022","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111069_bb1505","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1001\/jamaneurol.2016.4899","article-title":"Association of Docosahexaenoic Acid Supplementation with Alzheimer Disease Stage in apolipoprotein E \u03b54 carriers: a review","volume":"74","author":"Yassine","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.pnpbp.2024.111069_bb1510","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.neuropharm.2015.02.020","article-title":"Donepezil attenuates Abeta-associated mitochondrial dysfunction and reduces mitochondrial Abeta accumulation in vivo and in vitro","volume":"95","author":"Ye","year":"2015","journal-title":"Neuropharmacology"},{"issue":"12","key":"10.1016\/j.pnpbp.2024.111069_bb1515","doi-asserted-by":"crossref","DOI":"10.3390\/molecules27123737","article-title":"Neuroprotective effect of caffeine in Alzheimer\u2019s disease","volume":"27","author":"Yelanchezian","year":"2022","journal-title":"Molecules"},{"issue":"3","key":"10.1016\/j.pnpbp.2024.111069_bb1520","doi-asserted-by":"crossref","first-page":"11","DOI":"10.20517\/and.2022.16","article-title":"Tau-targeting therapy in Alzheimer's disease: critical advances and future opportunities","volume":"2","author":"Yi","year":"2022","journal-title":"Ageing Neur. Dis."},{"issue":"1","key":"10.1016\/j.pnpbp.2024.111069_bb1525","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/s41598-018-19641-2","article-title":"Cromolyn reduces levels of the Alzheimer\u2019s disease-associated amyloid \u03b2-protein by promoting microglial phagocytosis","volume":"8","author":"Zhang","year":"2018","journal-title":"Sci. Rep."},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111069_bb1530","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1038\/s41593-019-0372-9","article-title":"Senolytic therapy alleviates A\u03b2-associated oligodendrocyte progenitor cell senescence and cognitive deficits in an Alzheimer\u2019s disease model","volume":"22","author":"Zhang","year":"2019","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.pnpbp.2024.111069_bb1535","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s40035-016-0054-4","article-title":"The dual roles of cytokines in Alzheimer\u2019s disease: update on interleukins, TNF-alpha, TGF-beta and IFN-gamma","volume":"5","author":"Zheng","year":"2016","journal-title":"Transl. Neurodegener."},{"issue":"5","key":"10.1016\/j.pnpbp.2024.111069_bb1540","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1142\/S0192415X23500507","article-title":"Pharmacological effects of ginseng: multiple constituents and multiple actions on humans","volume":"51","author":"Zhou","year":"2023","journal-title":"Am. J. Chin. Med."},{"issue":"11","key":"10.1016\/j.pnpbp.2024.111069_bb1545","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.7150\/jca.29528","article-title":"Regulatory molecules and corresponding processes of BCR-ABL protein degradation","volume":"10","author":"Zhu","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.pnpbp.2024.111069_bb1550","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.trci.2018.09.009","article-title":"A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer\u2019s disease: a pilot study","volume":"4","author":"Zhu","year":"2018","journal-title":"Alzheimers Dement. (N Y)"},{"issue":"10","key":"10.1016\/j.pnpbp.2024.111069_bb1555","article-title":"Exploring Epigallocatechin-3-Gallate autoxidation products: specific incubation times required for emergence of anti-amyloid properties","volume":"11","author":"Ziaunys","year":"2022","journal-title":"Antioxidants (Basel)"},{"key":"10.1016\/j.pnpbp.2024.111069_bb1560","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.113818","article-title":"Development of novel phosphodiesterase 5 inhibitors for the therapy of Alzheimer\u2019s disease","volume":"176","author":"Zuccarello","year":"2020","journal-title":"Biochem. Pharmacol."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584624001374?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584624001374?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,8,10]],"date-time":"2024-08-10T08:54:37Z","timestamp":1723280077000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584624001374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":317,"alternative-id":["S0278584624001374"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2024.111069","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Alzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2024.111069","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"111069"}}